Independence Blue Cross and the Colorectal Cancer Alliance announced a cancer screening and prevention program which aims to address the decrease in colorectal cancer screening rates among Black Philadelphians since the pandemic started.
Stand Up To Cancer appointed five new members to the SU2C Health Equity Committee. SU2C established the Health Equity Committee in 2018, a year after it began developing its Health Equity Initiative. The initiative was formally announced in 2020.
In a panel discussion this week, four cancer centers directors described how their experiences as immigrants have shaped their approach to oncology and the U.S. healthcare system.
A commentary authored by seven researchers who participated in the FDA Oncology Center of Excellence “Conversations on Cancer,” held July 29, 2021, discussed the significant cancer disparities facing Asian Americans.
The Cancer Care Is Different Coalition announced its support for the California Cancer Care Equity Act (SB 987), which would remove regulatory barriers that disproportionately prevent Californians in underserved communities from accessing optimal cancer care for complex cancer diagnoses.
Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID-19. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough infections after receiving the vaccine.
Worry not, because support for cancer research remains strong, NCI Director Ned Sharpless said, even as the institute stalls in its attempts to increase paylines in fiscal year 2022 and as the White House requests a nearly $200 million cutto the FY23 NCI budget.
Cancer mortality fell by 2.1% between 2018 and 2019, compared to a 2.4% relative decrease in the year prior, according to the American Cancer Society’s 2022 Cancer Statistics report.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants, with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to ensuring that TMIST trial results will be applicable across races, ethnicities, and under-served communities.
An outreach program at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) is mailing free at-home colon cancer screening tests to Black primary care patients who have not yet had their routine colonoscopy.
